Tirzepatide is a single engineered peptide that binds two different incretin receptors at once. This article examines what preclinical and clinical research reports about how that dual engagement reshapes insulin secretion, glucagon output, and energy balance in experimental and trial settings.

The incretin effect and why it matters

When glucose is delivered orally rather than intravenously, the pancreas releases substantially more insulin for the same blood-glucose level. This difference — the incretin effect — is attributed to two gut peptides secreted in response to nutrients: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).¹ A functioning entero-insular axis, in which these hormones signal from gut to endocrine pancreas, is considered essential for normal glucose tolerance.¹

In type 2 diabetes the incretin effect is markedly reduced, even though circulating GIP and GLP-1 concentrations are more or less preserved.¹ This observation has driven decades of research into whether restoring or amplifying incretin signaling pharmacologically could improve glucose regulation — the conceptual foundation on which tirzepatide was built.

GIP and GLP-1: two hormones, complementary signals

Although both are classed as incretins, GIP and GLP-1 are not interchangeable. GIP is secreted from enteroendocrine K cells in the upper small intestine; GLP-1 is released from L cells more distally. Both augment glucose-dependent insulin secretion, and their insulinotropic actions are described as additive.¹

Their effects diverge on other axes. Reviews of incretin pathophysiology note that GLP-1 suppresses glucagon secretion during hyperglycaemia, whereas GIP can raise glucagon during hypoglycaemia — each acting in a glucose-dependent manner.¹ GLP-1 slows gastric emptying and, at pharmacological levels, reduces appetite and food intake; GIP has a more prominent role in adipose-tissue lipid handling.¹² The rationale for combining the two, articulated in mechanistic reviews, is that engineering GLP-1 activity alongside GIP pharmacology may broaden the metabolic index beyond what a selective GLP-1 receptor agonist achieves.²

How tirzepatide engages both receptors

Tirzepatide (development code LY3298176) is a 39–amino-acid synthetic peptide modified with a C20 fatty-diacid moiety that supports once-weekly pharmacokinetics. It was designed as a single molecule with agonist activity at both the GIP and GLP-1 receptors.³ In the discovery work, the compound activated both receptors in cell-based signaling assays and, in mice, produced glucose-dependent insulin secretion and improved glucose tolerance through action at both receptors; chronic dosing reduced body weight and food intake more than a GLP-1 receptor agonist comparator.³

Its pharmacology is not symmetric. Detailed receptor-occupancy and signaling analysis characterises tirzepatide as an imbalanced and biased dual agonist.⁴ At clinically relevant doses it engages the GIP receptor to a greater degree than the GLP-1 receptor. At the GIP receptor it behaves much like native GIP, whereas at the GLP-1 receptor it shows bias — favouring cAMP generation over β-arrestin recruitment, with weaker receptor internalization than GLP-1 itself.⁴ Experiments in primary islets in that study suggested β-arrestin1 normally limits the insulin response to GLP-1 but not to GIP or tirzepatide, offering one proposed explanation for the compound’s insulin-secretory profile.⁴

Downstream effects: insulin, glucagon and glucose handling

The convergent output of dual receptor engagement, as reported across preclinical and clinical work, is enhanced glucose-dependent insulin secretion.³ Because insulin release is coupled to prevailing glucose, the mechanism is described as producing insulin secretion primarily when glucose is elevated — a property associated in trials with low rates of clinically significant hypoglycaemia.⁶

Beta-cell function and insulin sensitivity

A post-hoc mechanistic analysis of a phase 2 program reported that, compared with the selective GLP-1 receptor agonist dulaglutide, tirzepatide was associated with greater improvements in markers of beta-cell function (HOMA2-B) and reduced proinsulin-to-insulin and proinsulin-to-C-peptide ratios.⁵ Markers of insulin sensitivity — adiponectin, IGFBP-1 and IGFBP-2 — increased. Notably, multiple-regression analysis in that report attributed only 13–21% of the improvement in insulin resistance to weight loss, suggesting the dual-receptor pharmacology may contribute mechanisms distinct from weight change alone.⁵

Glucagon

Reviews of the co-agonist mechanism note reductions in prandial insulin and glucagon concentrations relative to a selective GLP-1 comparator, consistent with the GLP-1 arm’s glucose-dependent glucagonostatic effect.¹⁰ Lower glucagon output is linked mechanistically to reduced hepatic glucose production and improved fasting glucose, though the relative weighting of GIP versus GLP-1 contributions to this effect in humans is not fully resolved.¹⁰

Appetite, gastric emptying and adipose signaling

Beyond the pancreas, incretin receptors are expressed in brain regions that regulate food intake, and reviews describe both GIP and GLP-1 as capable of influencing satiety signaling.¹ GLP-1 receptor activation slows gastric emptying, which blunts post-meal glucose excursions, and reduces appetite. GIP is additionally implicated in adipose-tissue lipid storage and regional blood-flow effects.¹ In rodent studies, dual-agonist exposure decreased food intake and body weight more than a GLP-1 receptor agonist alone;³ whether the added GIP component reproduces those appetite and weight effects in humans is one of the field’s central open questions.¹⁰ Related dual and triple incretin research programs — for example retatrutide, a GIP/GLP-1/glucagon receptor agonist under study — extend this line of investigation further.

What the clinical trials measured

The molecule has been studied extensively in randomized controlled trials (the SURPASS program in type 2 diabetes and SURMOUNT in obesity). The table below summarises reported changes from representative trials; values are trial outcomes for the prescription medicine, provided here as scientific context, not as outcomes attributable to any Qovigen product.

In the head-to-head SURPASS-2 trial, tirzepatide was reported as noninferior and statistically superior to semaglutide 1 mg for HbA1c reduction, with greater accompanying weight change.⁷ This comparison is frequently cited when researchers contrast dual-agonist pharmacology against a selective GLP-1 receptor agonist such as semaglutide. Across the program, the most common reported adverse events were gastrointestinal — nausea, diarrhoea and vomiting — described predominantly as mild to moderate and occurring largely during dose escalation.⁶⁷ A meta-analysis across the trial program reported no hazard ratio above 1.0 for adjudicated major adverse cardiovascular events versus pooled comparators, though event numbers were low and dedicated cardiovascular-outcome data continue to accrue.¹⁰

Open questions: the GIP paradox

A persistent puzzle sits at the centre of the dual-agonist story. GIP’s acute insulinotropic activity is known to be substantially attenuated in people with type 2 diabetes, for reasons that remain incompletely understood.¹ If GIP receptor signaling is impaired in the very population being studied, why a GIP component should add value is not fully explained by classical incretin physiology.¹⁰ Reviews note that appetite- and weight-lowering effects of GIP demonstrated in rodents have not been consistently confirmed in humans, keeping the mechanistic weighting of the two receptor arms an active research area.¹ Contemporary mechanistic reviews continue to map how sustained co-activation of the two receptors interacts over time and how receptor bias may shape outcomes.¹¹ These questions are precisely why tirzepatide remains a subject of laboratory investigation rather than a settled mechanism.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.